Lyra Therapeutics (LYRA) Tops Q3 EPS by 4c

Lyra Therapeutics (NASDAQ: LYRA) reported Q3 EPS of ($0.18), $0.04 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $195 thousand versus the consensus estimate of $315.6 thousand.

For earnings history and earnings-related data on Lyra Therapeutics (LYRA) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• UDynamics files for Nasdaq IPO of 5.6 million shares at $5-$7 per share
• OSR Health faces Nasdaq delisting, plans appeal and $15M put option